Transmembrane sodium (Na þ ) fluxes and intracellular sodium homeostasis are central players in the physiology of the cardiac myocyte, since they are crucial for both cell excitability and for the regulation of the intracellular calcium concentration. Furthermore, Na þ fluxes across the membrane of mitochondria affect the concentration of protons and calcium in the matrix, regulating mitochondrial function.
mitochondria affect the concentration of protons and calcium in the matrix, regulating mitochondrial function. In this review we first analyze the main molecular determinants of sodium fluxes across the sarcolemma and the mitochondrial membrane and describe their role in the physiology of the healthy myocyte. In particular we focus on the interplay between intracellular Ca 2þ and Na þ . A large part of the review is dedicated to discuss the changes of Na þ fluxes and intracellular Na þ concentration([Na þ ] i ) occurring in cardiac disease; we specifically focus on heart failure and hypertrophic cardiomyopathy, where increased intracellular [Na þ ] i is an established determinant of myocardial dysfunction. We review experimental evidence attributing the increase of [Na þ ] i to either decreased Na þ efflux (e.g. via the Na þ /K þ pump) or increased Na þ influx into the myocyte (e.g. via Na þ channels). In particular, we focus on the role of the "late sodium current" (I NaL ), a sustained component of the fast Na þ current of cardiac myocytes, which is abnormally enhanced in cardiac diseases and contributes to both electrical and contractile dysfunction. We analyze the pathophysiological role of I NaL enhancement in heart failure and hypertrophic cardiomyopathy and the consequences of its pharmacological modulation, highlighting the clinical implications. The central role of Na þ fluxes and intracellular Na þ physiology and pathophysiology of cardiac myocytes has been highlighted by a large number of recent works. The possibility of modulating Na
is the principal cation in the extracellular milieau and its highly regulated movement across the membrane of cardiac myocytes is the primary determinant of action potential (AP) upstroke and is essential for autoregenerative impulse propagation throughout the myocardium. In order to support cell excitability a large Na þ gradient across the membrane needs to be maintained.
Thus intracellular sodium concentration ([Na 2þ ] i ) within the cardiac myocyte must be accurately controlled and is finely regulated by a number of channels and transporters. 1 Despite that Na þ has been classically seen solely as a regulator of cardiac excitability, [Na 2þ ] i is an important modulator of numerous aspects of cardiomyocyte function, from excitation-contraction coupling to energy production and consumption. In fact, [ ] i strictly regulates the concentration of Ca 2þ within the mitochondria, a major determinant of the rate of ATP production and the generation of reactive oxygen species (ROS). Great interest has been recently devoted to the study of Na þ homeostasis since [Na 2þ ] i can be dysregulated in cardiac disease and its dysregulation may strongly contribute to their pathophysiology. As an example, increased [Na 2þ ] i has been observed during ischemia 2 -5 and abnormally high [Na 2þ ] i was identified as a contributor to ischemia-reperfusion injury. Increase of [Na 2þ ] i has also been observed in different models of heart failure (HF). 6 -9 HF is characterized by a global dysregulation of Ca 2þ homeostasis 10 : increased [Na 2þ ] i has been suggested to contribute to altered Ca 2þ handling, which in turn is the main determinant of the altered contractility and arrhythmias in HF. In this pathological setting, intracellular Na 2þ overload and Ca 2þ overload go hand in hand and may constitute a vicious circle. [Na þ ] i not only controls contractility and arrhythmogenicity but also regulates cardiomyocyte energetics via control of mitochondrial function: Na 2þ overload may also contribute to energetic insufficiency and excessive production of ROS in cardiac diseases. For all these reasons, every therapeutic attempt aimed at normalizing Ca 2þ homeostasis without addressing Na 2þ overload is destined to fail. Actual therapeutic options for heart failure and other cardiac diseases mainly affect Ca 2þ homeostasis and are incapable of reducing arrhythmogenesis and ameliorating contractile function of diseased hearts. Besides the direct electrophysiological effects, the possible global benefits of the inhibitors of Na þ channels and carriers, are therefore of utmost interest and are being investigated in many disease settings. 11 This review will focus on the regulation of [Na 2þ ] i in healthy myocardium and on its alterations in cardiac diseases such as heart failure and hypertrophic cardiomyopathy. Moreover, we will review the evidence supporting novel therapeutic options aimed at normalizing Na 2þ homeostasis in different cardiac diseases and their relevance for the clinical management of cardiac patients.
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The capability of measuring intracellular [Na þ ] i and its variations in response to pathological changes of cell function is essential to understand the role of Na þ in the heart. Early approaches to [Na þ ] i measurement involved the use of Na þ selective microelectrodes, 12 which are quantitatively precise but require direct probing of the desired cell with an impaling electrode, limiting its use in contracting tissue. Recently, the use of Na þ selective fluorescent indicator dyes has become the approach of choice. Up to 2011, the most widely used Na þ indicator was SBFI, 13 which has been used both in single cells 4 and in intact myocardium. 14 The dye is intrinsically ratiometric, being similar to the Fura- ] i modulation in disease conditions. We will now focus on the role of these influx and efflux pathways in the normal heart. A cartoon describing Na þ homeostasis in the healthy cardiomyocyte is shown in Figure 1 . Na 1 channels: peak and late Na 1 current
When electrotonic propagation from the neighboring cells depolarizes the cell membrane to reach the threshold for Na þ channel voltage-dependent activation, a large number of channels open giving rise to a huge depolarizing current (, 20-30 nA/pF at peak), which determines the upstroke phase of the AP. Therefore, the principal role of Na þ channels is to allow the AP to initiate and permit propagation of the AP throughout the myocardium. This current is generally short lived because the intrinsic timedependent inactivation of Na þ channels determines their fast closure at the beginning of AP plateau.
However, since the current is very large, a non-negligible amount of Na þ is transferred inside the cytosol at each activation. Their contribution to [Na þ ] i is obviously directly dependent on the rate of activation: the higher the heart rate, the larger the total amount of Na þ entering through the Na þ channel. The most represented isoform of Na þ channel in the heart is the so called "cardiac" Na þ channel NaV1.5 (SCN5a gene), which has a relatively low affinity for the selective blocker Tetrodotoxin (TTX). However, recent work identified other isoforms of Na þ channels in the heart, in particular neuronal isoforms such as NaV1.1, NaV1.3 and NaV1. 7, 19 which are all largely more sensitive to TTX. Meier et al. found that neuronal channels, despite contributing for only 10% to total peak Na þ current, have a high density in the membrane of t-tubules and may thus be important for t-tubular propagation of the AP. 20 However, selective inhibition of neuronal isoform in the heart with TTX at low concentration (, 0.5 mM) showed that neuronal channels are not essential for a proper AP upstroke and efficient excitation-contraction coupling in the cardiomyocyte. 21 These investigations are made difficult by the fact that, in stimulated preparations (such as isolated myocytes), the sodium channel might not be necessary for cell contraction since the electrical stimulation might also activate the calcium channel directly. 22 Therefore, the exact role of neuronal Na þ channels in the normal heart remains to be clarified. Several experiments pointed out that inhibition of the Na þ current with TTX not only reduces the maximal upstroke velocity of the AP but also shortens the plateau: these observations mean that a sustained component of Na þ current is somewhat involved in determining the balance of inward and outward currents that influence AP plateau. 23 Two main mechanisms underlie the sustained component of Na 33, 34 and sinus node cells. 35 In normal myocytes, I NaL is generally very small (30 pA at 0 mV) but it may be enhanced 3 to 5 fold in pathological conditions (see below). 36 I NaL has been demonstrated to be brought about by the same Na þ channels that are responsible for the peak current, i.e. NaV1.5. Indeed, when only NaV1.5 channels are re-expressed in cell vectors, I NaL can be recorded. 37 However, a recent work pointed out that 44% of the late sodium current in cardiac myocytes from dog ventricle is due to non-cardiac-type Na þ channels, such as neuronal isoforms NaV1.1 or NaV1.3 or skeletal muscle isoform NaV1. 4 . 38 Single channel studies demonstrated that two mechanisms are involved in determining I NaL : (i) burst openings, which undergo voltage-dependent inactivation and (ii) scattered openings, which inactivate extremely slowly and therefore are able to determine a truly "background" Na þ current. The first mechanism is the most represented in the human. 37 I NaL is also strongly rate dependent, in that it is reduced at faster rates of activation, suggesting inactivation and incomplete recovery of the current. 34 Albeit very small when compared to peak current, I NaL can significantly contribute to determine [Na þ ] i since its duration is several orders of magnitude longer. During a single AP, a normal I NaL may increase the amount of Na þ flowing into the cell by 50% on top of the inflow occurring during the AP upstroke. As discussed later, this is of utmost importance in conditions where I NaL is increased and its contribution to the total Na þ inflow increases significantly.
In summary, the total amount of Na þ entering the cell through the Na þ channels is essentially proportional to the rate of activation and to the density of I NaL .
Na
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/Ca 21 exchanger (NCX)
NCX employs the energy provided by Na þ entering the myocyte following its electrochemical gradient to transport Ca 2þ outside the cell. It is essentially aimed at maintaining a regular Ca 2þ homeostasis by allowing the excess of Ca 2þ to flow out of the cell against its electrochemical gradient. 39 In fact, NCX is the major outflow pathway for Ca 2þ and is crucial to maintain an equilibrium between Ca 2þ entering the cell through the Ca 2þ channel and Ca 2þ leaving the cell via the exchanger, which must be equal in steady-state conditions. Rate and function of the NCX depend on the intracellular and extracellular concentrations of both Na þ and Ca 2þ and are also influenced by the membrane potential. At negative resting potentials, when most of the Ca 2þ outflow occurs, the electrochemical gradient of Na þ and Ca 2þ favors the "forward" mode of the NCX: three sodium ions are brought inside the cell to extrude a single Ca 2þ with a net inflow of one positive change. If Ca 2þ inside the cell increases for any reason, such as an increase of Ca 2þ current, so does the activity of the NCX, thereby increasing the amount of Na þ flowing into the cell through the exchanger. 40 Moreover, the activity of NCX can be reduced by decreased pH and potentiated by ATP: in ischemic conditions, when pH and ATP are relatively lower, NCX activity can be seriously impaired. 41, 42 Though NCX mainly operates in the forward mode, at potentials positive to the NCX reverse potential (, 2 10 mV), the exchanger can also operate in the reverse mode, producing entry of calcium ions coupled to outflow of Na þ . This phenomenon however is likely to play a minor role in the healthy myocyte: in fact, though membrane depolarization during upstroke and plateau could potentially support reverse mode, the concurrent increase of intracellular [Ca 2þ ] due to Ca 2þ -induced Ca 2þ -release from the SR antagonizes Ca 2þ inflow through the NCX. In conditions where [Na þ ] i is higher and Ca 2þ release from the SR is reduced NCX reverse mode may play an increased role, as discussed later.
NHE is also capable of exploiting the energy of Na þ gradient to pump H þ out of the cell by letting Na þ flow into the cell. 43 -45 When pH is reduced, the activity of NHE increases in order to bring back pH to normal levels, making the NHE one of the main molecular modulators of cellular pH. Protons directly stimulate the exchanger, but NHE has been shown to be modulated by the intracellular signaling cascade mediated by a number of hormones, neurohormonal agonists and growth factors. 46 In conditions of intracellular acidosis, NHE can significantly contribute to increase Na þ entry and [Na þ ] i within the myocyte.
Na þ removal through the NCX is non-relevant in normal conditions, therefore the main mechanism able to pump the excess of intracellular Na þ out of the cell is the NKA. 47 NKA is essential to maintain the gradients of Na þ and K þ across the membrane and to allow myocardial excitability. Using the energy liberated by the hydrolysis of ATP, the NKA is able to extrude 3 intracellular Na þ ions while bringing 2 extracellular K ions inside the cytosol, thus moving one net charge per cycle. The NKA is characterized by two major subunits, a and b: the a subunit features the binding site for ATP, K þ , Na þ and cardiac glycosides, while the b is essential for a proper membrane localization and insertion. Different a subunit isoforms with different affinity for ATP and ions exist in the heart and their relative expression can be modulated by cardiac diseases. 47 Interestingly, the rate of NKA can be actively modulated by a small membrane bound protein similar to phospholamban (the main modulator of sarcoplasmic reticulum Ca 2þ ATPase -SERCA-), called phospholemman (PLM). PLM, like phospholamban, is abundant in the heart and can be phosphorylated following activation of b-adrenergic cascade. 48 When PLM interacts with the NKA, it reduces the activity of the a subunit, ultimately reducing Na þ extrusion rate. This has been demonstrated via phospholemman knock-out in cardiac cells, which led to an increase of NKA activity of the same extent as maximal b-adrenergic stimulation. 49 These observations suggest that PLM, like phospholamban, detaches from the NKA when phosphorylated by protein kinase A, relieving the specific inhibition.
Mitochondrial Na 1 outflow and inflow mechanisms
The main Na 2þ efflux mechanism from the cytosol to the mitochondria in the cardiac myocyte is the mitochondrial Na þ /H þ exchanger (mNHE). 50 The electron transport chain leads to extrusion of protons from the mitochondrial matrix to the cytosol. The mNHE senses the excess of protons on the cytosolic side of mitochondrial membrane and brings back H þ ions into the matrix while extruding Na þ ions from the mitochondria. From this observation stems the assumption that mitochondrial [Na þ ] is around 2 times lower than cytosolic [Na þ ] in the intact cell, an assumption that has been experimentally confirmed in isolated mitochondria and permeabilized myocytes. 50 In line with this observation, metabolic inhibition, via reduction of the activity of the electron transport chain, abolishes the net flow of Na þ across the mitochondrial membrane and leads to an equal [Na þ ] in mitochondria and cytosol.
Under normal conditions, it is unlikely that mitochondria contribute substantially to the regulation of [Na þ ] i . However, in conditions of increased metabolic activity, due to the higher pH gradient across the mitochondrial membrane, the increased activity of the mNHE could actually lead to transient changes
The major mechanism involved in Na þ influx to the mitochondria is the mitochondrial Na þ /Ca 2þ exchanger (mNCX). Like the sarcolemmal NCX, mNCX is electrogenic and transports 3 sodium ions from the cytosol to the mitochondrial matrix while extruding a single Ca 2þ from the mitochondrion to the cytosol. 51 -55 What provides the driving force for such an exchange given the fact the [Na 2þ ] gradient across the mitochondrial membrane is relatively small? Active mitochondria have a very large membrane potential with inward direction, ranging from 2 150 mV to 2180 mV. This large DV provides the driving force for mNCX function in the forward direction. Interestingly, the mNCX never reaches the equilibrium in the intact cell:
] ¼ 300nM (average values for an active myocyte), mitochondrial [Ca 2þ ] would be as low as 1 nM at equilibrium. 56 However, the measured mitochondrial [Ca 2þ ] in the intact active myocardium is usually above 150 nM. 57 There are multiple reasons explaining why the mNCX does not operate at equilibrium: (i) the Ca 2þ uniporter continuously brings calcium ions inside the mitochondrion following the favorable electrochemical gradient for Ca 2þ across the mitochondrial membrane and (ii) the activity of mNCX is much lower than that of the Ca 2þ uniporter. When the uniporter is blocked by Ruthenium or by an excess of magnesium, mNCX approaches the equilibrium and mitochondrial [Ca 2þ ] is strongly reduced. 54 ] inside the mitochondria activates the enzymes of the oxidative metabolism thus leading to an increased production of NADH, which in turn increases the function of the electron transport chain, ultimately determining higher rate of ATP production. 56 Ca 2þ can also directly activate the macromolecular components of the electron transport chain. 58 ] i may have important deleterious consequences on arrhytmogenesis, contractility and energetics. We will now discuss the mechanisms involved in Na þ dysregulation in heart failure and the possible therapeutic role of pharmacological modulation of Na þ fluxes and homeostasis. A cartoon depicting Na þ regulation in HF is shown in Figure 2 .
Abnormal Ca 21 handling in heart failure
In order to understand the implications of abnormal Na þ homeostasis in HF we have to keep in mind the large Ca 2þ dysregulation occurring in HF myocytes. Most models of HF, including human, are characterized by decreased SR Ca 2þ -ATPase (SERCA) expression and upregulation of NCX expression and function (Figure 3 ). On the other hand, Ca 2þ current is generally unmodified. 61 Phospholamban (PLB) is the major modulator of SERCA function and its expression is typically unaltered in HF, 62, 63 with decreased phosphorylation. The subsequent increase of PLB:SERCA ratio, coupled with the lower PLB phosphorylation, enhances the inhibitory effect of PLB on SERCA, contributing to lower SERCA function in HF. Decreased SERCA activity, by slowing down Ca 2þ reuptake to the SR, allows more Ca 2þ to be extruded via the NCX; coupled with the increased NCX expression 64 this results in a net loss of cell Ca 2þ and contributes to the reduction of SR Ca 2þ load in HF. 65 Another contributor to the lower SR Ca 2þ content in HF is the increased diastolic leakage of Ca 2þ from the SR, which is determined by the hyper-phosphorylation of ryanodine receptors (RyRs) by protein-kinase A (PKA) and/or Ca 2þ -Calmodulin dependent protein kinase-II (CaMKII). 66 CaMKII activity is increased in HF, and CaMKII-dependent phosphorylation of RyR enhances Ca 2þ spark frequency and thus spontaneous diastolic SR Ca 2þ leak, 67 making it one of the leading pathway causing contractile dysfunction and arrhythmogenesis in HF. Enhanced NCX function, combined with the higher probability of spontaneous Ca 2þ release from the SR, contributes directly to arrhythmogenesis via delayed-afterdepolarizations (DADs). When a large spontaneous Ca 2þ release event occurs during diastole giving rise to a generalized Ca 2þ wave, part of the released Ca 2þ is extruded through the NCX, which generates an inward current that depolarizes the membrane (i.e. a DAD). If large enough, a DAD may reach the threshold for a premature AP, giving rise to a premature activation that can propagate through the myocardium, triggering sustained arrhythmias. As explained below, abnormal Na þ homeostasis may further increase the risk of arrhythmias in HF with multiple mechanisms.
Alterations of late Na 1 current in HF Increased [Na þ ] i in HF may be due to increased Na þ influx or decreased Na þ efflux. Early studies suggested that an excess of Na þ influx is the major contributor to Na þ overload and the main source of the increased Na þ entry is the enhanced "late" or "persistent" Na þ current. 7, 8 As explained before, a component of Na þ current with slow or incomplete inactivation can be measured in normal human and animal cardiac myocytes. 26 However, acquired and primary cardiac diseases are commonly characterized by abnormally large I NaL . Enhancement of late Na þ current has been identified in many models of disease and may contribute to their pathogenesis: besides classical LQT3 syndrome, which is due to Na þ channel mutations, 68 increase I NaL was also found as a consequence of ankyrin B mutations (LQT4 syndrome) 69 and caveolin-3 mutations (LQT-CAV3), 70 suggesting that the altered function of proteins linked to the Na þ channel can affect its function in a way similar to its own mutations. Moreover, abnormally large I NaL was found in cells from hearts of patients affected by end stage HF, 26, 71 in animal models of HF 72 -74 and following myocardial infarction. 74 Hypoxia, 75 oxygen free radicals (H 2 O 2 ), 76 ischemic metabolites (like oxidized lipids) 77 and nitric oxide (NO) 78 have been shown to rapidly and directly increase I NaL in experimental conditions, suggesting that peroxydation or nitrosylation of channels may directly alter their inactivation kinetics. Moreover, increased Ca 2þ -Calmodulin 79 and calmodulin kinase II (CaMKII) activity, 27 both common features of myocardial remodelling in HF, have been shown to increase I NaL . Recent evidence identified CaMKII-mediated phosphorylation of cardiac Na þ channels at multiple sites is the main regulator of Na þ channel inactivation. 80 Increased levels of phosphorylation at those sites may therefore be the main responsible for the enhancement of I NaL in HF and other diseases. The effects of oxidative stress on I NaL also seem to be mediated by enhanced CaMKII-mediated phosphorylation due to the intrinsically active oxidized CamKII. 81 From a molecular standpoint, enhanced I NaL in HF is mediated by an increase of bursts and scattered late openings in single NaV1.5 channels, 37 i.e. the same mechanisms found in normal myocytes, although with higher gating rates. All this suggests that in HF, I NaL enhancement is not mediated by expression of different Na þ channel isoforms other than Nav1.5. In contrast with that, 59 and force twitch from Sossalla et al. 60 in a rat model of pressure overload-induced hypertrophy and failure it was shown that the increased I NaL is associated with a large up-regulation of neuronal Na þ channels (Nav1.1, Nav1.3, and Nav1.6) in the ventricle. 82 Whatever the reason of I NaL enhancement, this condition is always associated with a prolonged repolarisation causing a remarkable increase in AP duration, 72, 83 with increased rate-dependent AP shortening and temporal variability of AP duration. 71, 84 AP prolongation leads to reduced repolarisation reserve and therefore increased incidence of early afterdepolarizations (EADs, i.e. premature depolarizations occurring during the plateau phase) and potentially fatal arrhythmias. 85 Previously mentioned cardiac conditions, including HF, are all characterized by increased susceptibility to perturbations of repolarisation (e.g. drugs blocking K þ currents or electrolyte imbalances) and overall increased risk of arrhythmias. I NaL is an inward current occurring during action potential plateau, when the membrane potential is sensitive to small current changes since the stabilizing effect of I K1 is absent. From this stems the marked slowing effect of increased I NaL on the rate of repolarization. A slower phase 3 repolarization is a strong predictor of arrhythmic risk, 86 likely because it prolongs the time spent in partial refractoriness (the so called "vulnerable window"). The increased rate of EADs in the presence of increased I NaL is likely a direct consequence of the resulting APD prolongation. Indeed, prolonged plateau phase allows calcium current (I CaL ) to recover from inactivation and reactivate, thus eliciting the postdepolarization. Prolongation and instability of repolarization in HF is also caused by other electrical abnormalities such as reduction of K þ currents. 87, 88 Due to the reduced repolarizing currents, the effects of I NaL prolongation are more deleterious in HF than in control myocytes. 26 Thus even a minor inhibition of K þ currents would result in a severe AP prolongation: I NaL thus contributes to the increased susceptibility to AP prolonging agents in HF (i.e. reduced repolarization reserve), contributing to drug-induced pro-arrhythmia. So far we have discussed only the potential deleterious electrophysiological consequences of I NaL augmentation in HF; however, the most severe consequences of the increased I NaL are associated with intracellular Na þ overload. The total amount of Na þ ions entering the cell through Na þ channels is a function of the current amplitude multiplied by its duration. Though the amplitude of I NaL is small, it lasts for a very long time when compared to peak current, leading to an increase in Na þ influx ranging from 50% to 100% of peak I Na at each activation. 71, 89 Thus, I NaL may be the main responsible factor for the increased [Na þ ] i observed in failing myocytes.
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Alterations of NCX and NHE in heart failure In addition to the excess of Na þ entering the cell via Na þ channels, increased [Na þ ] i in HF may also rely on enhanced Na þ entry through the NCX or the NHE. As mentioned above, NCX is upregulated in HF and thus can potentially cause increased Na þ entry, especially if combined with the increased cytosolic
], which is often seen in failing myocytes due to the increased leakage from the SR. However, the contribution of the increased NCX function to the higher total [Na þ ] i in HF appears to be minimal, 6 for two main reasons: (i) the absolute of Na þ ions entering via the exchanger is relatively low and (ii) the increased forward mode activity of the NCX is counterbalanced by an increased reverse mode (see below), which may become relevant in HF. NHE instead is likely to play a more significant role; Baartscher et al. 9 reported that in a rabbit HF model, the increased [Na þ ] i can be inhibited by blocking the NHE with cariporide. The importance of this mechanisms is confirmed by several reports showing attenuated development of heart failure and related myocardial dysfunction when NHE inhibitors are used. 45, 90, 91 NHE activity may be increased in HF as a consequence of energetic imbalance leading to intracellular acidosis requiring an increased function of the sarcolemmal proton exchanger.
Alterations of NKA in heart failure On top of the increased Na þ influx, decreased Na þ efflux may contribute to increased [Na þ ] i in HF.
Several HF models are characterized by decreased global expression or shift in the isoforms of NKA. 91 Most of the studies however have been done on tissue homogenates and may reflect changes of non-cardiomyocyte protein levels. 92 Only a few studies of NKA function have been performed in HF myocytes, and the results are contradictory: in a model of rat post-myocardial infarction HF a reduced activity was reported, 93 while myocytes from a dog model displayed unaltered maximal NKA pump current. 94 Unaltered pump rate with similar Na þ affinity was also reported in a rabbit HF model 6 and found that both the maximal Na þ transport rate and the NKA affinity for internal Na þ were not altered, despite the reduced NKA expression in ventricular myocytes. 92 The presence of unaltered function despite less protein count suggests that NKA activity is regulated differently in HF. Indeed, in HF rabbit myocytes expression of phospholemman (PLM) is reduced, 92 determining lower PLM:NKA ratio; combined with the higher PLM phosphorylation, this results into less overall inhibition of NKA by PLM, explaining the maintained pump function. Similar changes of PLM expression and phosphorylation were also observed in human HF. 92 
Effects of increased I NaL and [Na 1 ] i on cardiomyocyte function
The previous observations on a number of HF models highlight the limited role of NCX and NHE in determining the increased Na þ entry and the absence of NKA functional alterations reducing global ] i leads to slower and incomplete myofilament inactivation and relaxation; this phenomenon is extremely more pronounced at high pacing rates, due to a more marked cytosolic Na þ and Ca 2þ overload. At high pacing rates, the extreme [Ca 2þ ] i overload extending throughout the entire diastolic period may severely impair relaxation, effectively provoking contractures. 101 3) Spontaneous Ca 2þ releases induced by [Ca 2þ ] i overload generate diastolic aftercontractions that further impair and delay relaxation. 102 A further consequence of the impaired diastolic function determined by enhancement of I NaL and [Na þ ] i overload is a reduction of myocardial blood flow perfusion. Due extrinsic compression of blood vessels by the contracting muscle, 103 myocardial coronary flow is limited during systole, and reaches a maximum during the initial relaxation phase. In HF, the early diastolic phase (isovolumic relaxation) is slower, due to the delayed decay of cytosolic Ca 2þ transient, myofilament force and wall stress. Increased I NaL may play a significant role in that phenomenon. Indeed, experimental I NaL enhancement by ATX-II determines reduced coronary blood flow 83 and pharmacological block of I NaL ameliorates perfusion. 101 The increase of [ ]. This results in reduced ATP production, thus creating a mismatch between ATP consumption and production. 104 In conclusion, increased I NaL not only directly affects cell electrophysiology but also alters Ca 2þ homeostasis with potential consequences for contractile function, cell metabolism and altered cell signaling leading to hypertrophic response.
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REGULATION IN HYPERTROPHIC CARDIOMYOPATHY
Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease, 108, 109 with a prevalence in the general population of 1:500, representing a leading cause of sudden cardiac death in the young 109 and a prevalent cause of heart failure and stroke. 110 Increased arrhythmogenesis and diastolic dysfunction are the two main pathophysiological features of this disease. 111 HCM is associated with a complex electrophysiological cardiomyocyte remodelling involving multiple changes in transmembrane currents ultimately leading to susceptibility to ventricular arrhythmias. We have recently characterized the electrophysiological, Ca 2þ handling and contractile abnormalities occurring in human HCM myocardium as concurrent determinants of diastolic dysfunction and arrhythmias in this disease. 17 We used isolated myocytes and intact trabeculae from myocardial specimens from the interventricular septum of HCM patients undergoing surgical myectomy, compared with non-hypertrophic surgical patients. Results of patch clamp studies showed that the action potential duration (APD) recorded at various frequencies of stimulation was markedly prolonged in cardiomyocytes from patients with HCM (HCM cardiomyocytes) compared to controls ( Figure 3A) . Prolonged APD was associated with prolonged QTc in patients from the HCM group (average QTc ¼ 470 ms). Of note, a recent large-scale study on HCM patients reported that QT prolongation is a common feature in patients with this disease 112 and may be a predictor of clinical outcome. Prolonged APD led to increased risk of early after depolarisations (EADs), 85 which were 6-fold more frequent in HCM cardiomyocytes than in control cells ( Figure 3B) . Interestingly, the degree of APD prolongation was associated with the frequency of ventricular arrhythmias in patients: patients with severely prolonged APD had a higher frequency of documented non-sustained ventricular tachycardia at 24 h ECG. 17 APD prolongation in HCM cardiomyocytes is determined by an imbalance between inward and outward transmembrane currents: repolarizing K þ currents were reduced and L-Type Ca 2þ current was increased. Importantly, we also observed that the amplitude of I NaL in HCM cardiomyocytes was larger compared to control patients, likely contributing to APD prolongation ( Figure 3C ). APD and ion current abnormalities determined significant alterations of intracellular Ca 2þ handling in HCM cardiomyocytes ( Figure 3D ). The amplitude of Ca ] i overload was accompanied by an increased rate of spontaneous Ca 2þ releases from the SR and DADs in HCM cardiomyocytes, thus contributing to arrhythmogenesis. Additionally, we found a slightly increased SR Ca 2þ content in HCM cardiomyocytes while the rate of Ca 2þ extrusion via NCX was reduced ( Figure 3F ). In keeping with this observation, we measured a negative shift of the reversal potential of NCX (E NCX ) that suggests increased [Na þ ] i ( Figure 3G ). Indeed, we reported an increased [Na þ ] i in HCM myocytes, directly assessed by virtue of fluorescence measurements with Asante Natrium Green 2 Na þ -selective dye. Based on this data, we suggested that in HCM enhanced I NaL -mediated Na þ influx leads to a sustained increase in [Na þ ] i , providing the driving force for an increased rate of Ca 2þ entry trough NCX, which is also overexpressed. However, increased [Na þ ] i also impairs forward-mode NCX function, leading to the observed reduction of Ca 2þ extrusion rate during caffeine exposure and likely contributing to slow down Ca 2þ transient decay and increase diastolic [Ca 2þ ] i , in combination with SERCA down regulation. The observed abnormalities of excitation-contraction coupling resulted in slower relaxation and increased diastolic tension in intact trabeculae isolated from the same samples. Interestingly, increased activity of CaMKII appears to underlie several of the observed changes in HCM cardiomyocytes: increased phosphorylation of Na þ channels determined enhanced I NaL , 27, 80 while increased RyR phosphorylation caused SR Ca 2þ leak and DADs. 66 We concluded that, among the several ion channels and EC-coupling protein changes, increase of I NaL and [Na þ ] i overload are major contributors to electro-mechanical cardiomyocyte dysfunction, which may be strongly associated with the increased arrhythmogenesis and diastolic dysfunction observed in HCM patients. Na þ dysregulation in HCM is described in the cartoon in Figure 4 .
ROLE OF PHARMACOLOGICAL I NAL INHIBITION IN CARDIAC DISEASES
Recent work highlighted the emerging role of I NaL in the pathogenesis of HF, hypertrophic cardiomyopathy and other cardiac diseases, making I NaL an interesting pharmacological target for disease management. We have previously highlighted the severe consequences of I NaL enhancement in terms of arrhythmogenesis and contractile dysfunction. I NaL inhibition may therefore improve both electrical and mechanical function of cardiomyocytes in many disease states. Therapeutic I NaL inhibition has been attempted in a number of conditions in which I NaL is abnormally enhanced, including LQT3, acute ischemia, experimental oxidative stress and heart failure 72,101,113 -116 : in all these, I NaL block determined shortening of APD, reduced temporal and spatial variability of repolarization and abolished EAD occurrence, highlighting a clear antiarrhythmic effect. Since I NaL is carried by cardiac Na þ channels, all drugs that interact with NaV1.5 channels affect I NaL . Indeed late Na þ current is inhibited by all classical Na þ channel blockers, comprising not only experimental agents such as Cd 2þ , Tetrodotoxin (TTX) and Saxitoxin (STX), 26, 71 but also clinically employed drugs. These include: (i) flecainide, 117, 118 which proved effective in shortening APD and reducing EADs in models of Long QT Type 3 (LQT3) syndrome induced by NaV1.5 mutations; (ii) mexiletine, 113, 119 which demonstrated a clear ability to prevent the occurrence of arrhythmias induced by experimental APD prolongation and reduced dispersion of repolarization in LQT3 120 ; (iii) lidocaine 121 and quinidine, 122 which effectively blocked genetically or experimentally enhanced I NaL . However, all of these drugs exert an effective I NaL block only at relatively high concentrations; at such concentrations, classical Na þ channel blockers also strongly inhibit peak Na þ current with great effects on myocardial excitability and conduction velocity. Under these conditions, the potential anti-arrhythmic effects of I NaL block may be overcome by the pro-arrhythmic consequences of the slower conduction. 122 Among classical Na þ channel blockers, flecainide displays the highest selectivity for the late component of Na þ current 117 ; however, the elevated pro-arrhythmic risk associated with flecainide use in structural heart diseases 123, 124 prevents its clinical use in conditions where I NaL is enhanced (heart failure, cardiomyopathies). Indeed flecainide, which inhibits peak Na þ current other than I NaL , causes significant conduction delay 125 and has been associated with increased mortality in post-myocardial infarction patients 126 : conduction slowing (induced by I Na peak block) combined with reduced refractoriness (due to shorter APD via I NaL block) favors reentry circuits. Amiodarone was shown to have I Na blockade capacity as an ancillary effect. Interestingly, amiodarone effectively blocked I NaL in cardiomyocytes from human failing hearts at concentrations as low as 5 mM, i.e. within the therapeutic range of the drug; amiodarone produced almost no effect on the transient Na þ current at these concentrations. 128 These results suggest that selective block of I NaL over peak current may mediate part of the anti-arrhythmic effects of amiodarone and contribute to limit its pro-arrhythmic toxicity, making it a relatively safe drug also in the presence of structural heart disease. 129 However, amiodarone is far from being a selective agent, in that exerts a potent blockade of repolarizing K þ currents (mainly I Kr ), with potential pro-arrhythmic consequences, 130, 131 especially when assumed in association with other QT prolonging drugs. As detailed above, in presence of severely increased I NaL , the APD prolonging effect of K þ current blockers is enhanced, raising the risk of proarrhythmic effects. 132, 133 From all these observations stems the need of a drug that blocks I NaL with high selectivity.
Developed in the 1990s as a cardiac specific partial fatty acid oxidation inhibitor, ranolazine was first experimented as a possible anti-anginal compound, with relatively good results. Ranolazine was found to be safe in humans in doses up to 2 grams/day, and it was effective in reducing symptoms in two clinical trials on chronic stable angina patients. 134, 135 It rapidly became clear that the anti-anginal and anti-ischemic effects of ranolazine were not due to the supposed metabolic effects (which are negligible at therapeutic concentrations), but rather to its selective blockade of the late sodium current. Its electrophysiological effects were in fact described in 2004 136 Ranolazine exerts an inhibitory effect on I Kr and a slight I CaL block 136 ; but the main effect was a potent inhibition of I NaL with small or no effect on peak I Na within the therapeutic concentration range. Inhibition of I Kr is generally considered pro-arrhythmic. However, in a large scale trial on non ST-elevation myocardial infarction patients, ranolazine significantly reduced the incidence of ventricular tachycardia 137 and was not associated with QRS prolongation or increased mortality in these patients. 138 Recent work showed that ranolazine inhibits triggered activity and its propagation in pulmonary veins, the main source of atrial ectopies, and reduces afterdepolarizations in atrial myocardium from surgical patients, 139 suggesting that ranolazine may also play a role in the prevention of atrial fibrillation. 140 These observations support the view that I NaL inhibition by ranolazine may be antiarrhythmic, even in the presence of a limited concomitant block of I Kr . I NaL , whose density is highly variable among different layers and regions of the ventricle, strongly contributes to spatial differences in repolarization. I NaL inhibition is therefore associated with a reduced transmural dispersion of repolarization, 136 contributing to its anti-arrhythmic effects. Ranolazine also inhibits other cardiac currents, including I CaL , I Ks , I K1 , I to and I NCX . 136 However, except for I CaL , the concentrations of ranolazine required to inhibit these other ion currents are at least 10-times higher than those required to block I NaL . Therefore, only inhibition of I NaL , I CaL and I Kr may contribute to ranolazine effects at therapeutic concentrations. Recently, a newly developed I NaL inhibitor (GS-458967) was shown to inhibit late current with a higher selectivity as compared with ranolazine, even at 10-times lower concentrations; GS-458967 effectively reduced experimentally induced cellular arrhythmias (EADs and DADs). 141 We have previously highlighted the multiple deleterious effects of increased I NaL on cardiomyocyte function. I NaL inhibition, via reduction of Na ] i leads to decreased [Ca 2þ ] i the resulting reduction of leak may improve the ability of the SR to reuptake Ca 2þ , thus preserving integrity of Ca 2þ store. I NaL inhibition has marked cardioprotective effects in conditions of myocardial ischemia, when increased activity of the NHE leads to increased Na þ influx. 143 Inhibition of I NaL may improve intracellular pH homeostasis by allowing a maintained rate of proton extrusion via the NHE. Finally, recent observations indicate that I NaL inhibition, via amelioration of relaxation and reduction of end-diastolic pressure, may significantly enhance coronary blood flow, especially in ischemic conditions. 83 In keeping with the favorable mechanical consequences of I NaL inhibition, ranolazine, unlike other anti-ischemic drugs, does not decrease the "double product" of arterial pressure and heart rate which is a valuable measurement of cardiac overall mechanical work. 144 In conclusion, recent evidence support the assumption that ranolazine markedly improves the contractile efficiency of diseased myocardium and increases coronary blood flow, independently of changes in cardiac work.
I NAL INHIBITION REVERSES ELECTRO-MECHANICAL DYSFUNCTION IN HYPERTROPHIC CARDIOMYOPATHY
Among the several changes identified in cellular electrophysiology and Ca 2þ handling in our recent study on human HCM cardiomyocytes, 17 we found that the increased late sodium current is amenable for a targeted correction by virtue of the selective blocker ranolazine. Since I NaL is potentially involved both in determining APD prolongation and Ca 2þ handling abnormalities leading to abnormal relaxation, I NaL inhibition is expected to positively affect both. In control cardiomyocytes, ranolazine (10 mM) did not significantly affect the APD and the effects of ranolazine on the amplitude and kinetics of Ca 2þ i transients were negligible. On the contrary, ranolazine significantly reduced APD in HCM cardiomyocytes ( Figure 5A) . Consistently, the occurrence of EADs in HCM cardiomyocytes was approximately halved by the application of ranolazine ( Figure 5B ). We found that ranolazine 10 mM markedly blocked I NaL in HCM myocytes, confirming that the described effects of the drug are consistent with specific I NaL inhibition. In HCM cardiomyocytes, the APD shortening by ranolazine was paralleled by accelerated rise and decay time of Ca 2þ i transients, associated with no significant decrease of Ca 2þ i transient amplitude ( Figure 5C ). Ranolazine significantly reduced intracellular diastolic [Ca 2þ ] i in HCM myocytes and attenuated the increase in diastolic [Ca 2þ ] i following increase in stimulation rate ( Figure 5D ). In agreement with these results, we found that ranolazine slightly reduced SR Ca 2þ -load in HCM myocytes and significantly accelerated caffeine-induced Ca 2þ i transients, suggesting an increased rate of Ca 2þ -extrusion through the NCX upon exposure to the drug ( Figure 5E ). The beneficial consequences of I NaL inhibition on Ca 2þ handing in HCM cardiomyocytes were mediated by a marked reduction of [Na þ ] i , as confirmed by direct assessment using Na þ -selective fluorescent indicators ( Figure 5F ). Reduced [Na þ ] i shifted E NCX back to positive levels, potentiating forward mode operation of the NCX. The beneficial effect of ranolazine was finally investigated in intact tissue measuring isometric twitch tension from intact ventricular trabeculae. 17 Ranolazine, speeded up the kinetics of force development and shortened the overall twitch duration. Further, it significantly diminished the rise of diastolic tension upon increase in stimulation frequency, without significantly reducing peak isometric (active) force. According to our results, by reducing [Na þ ] i overload, and thus diastolic [Ca 2þ ] I , ranolazine has the potential to improve diastolic function, a cause of symptoms in most HCM patients, and to indirectly improve myocardial perfusion, thus impacting on functional limitation and quality of life. Taken together these results highlight the great potential of I NaL inhibition for the reduction of arrhythmias and diastolic dysfunction in HCM patients.
In the long term, the effect on calcium homeostasis is expected to down regulate a number of remodelling pathways that strictly depend on myocyte driven signalling: this may in turn bring benefit to extracellular matrix remodelling, reducing fibroblasts growth and collagen production in 17 Baseline traces are black and the corresponding traces in the presence of ranolazine are red.
hypertrophied myocardium. In particular, reduction of intracellular Ca 2þ overload, may lead to sustained lower CaMKII activity, eventually affecting the functional and structural remodelling of HCM myocardium, with possible implications for disease progression. 145 In keeping with this observation, ranolazine administration has been shown to reduce the degree of myocyte hypertrophy and interstitial fibrosis in experimental hypertrophy models. 146 Thus, late sodium current inhibition in HCM may be capable of preventing disease progression towards the end-stage phase, by acting upon one of its most critical determinants -diastolic dysfunction, myocardial ischemia and fibrosis. In principle, late sodium current inhibition is the ideal therapeutic strategy for HCM patients, with a wide range of positive actions, which may have a critical impact on acute symptoms as well as on the natural history of the disease. The effects of ranolazine on HCM cardiomyocytes and the role of CaMKII are summarized in Figure 6 . pathophysiological situations such as heart failure and hypertrophic cardiomyopathy, contributing to contractile dysfunction and arrhythmogenesis. The progressive clarification of the involvement of I NaL in the pathogenesis of Na þ and Ca 2þ overload has rendered this current an appealing pharmacological target. The most significant advantage of I NaL inhibition is its potential to simultaneously target the consequences of disease-related functional changes (e.g., arrhythmias and contractile dysfunction) as well as the mechanisms underlying its progression (e.g., myocardial remodelling, ischemia). The potential therapeutic value of I NaL inhibition discussed in this review, in particular in heart failure and hypertrophic cardiomyopathy, still awaits confirmation from clinical trials. Whereas I NaL inhibitors have a proven efficacy in patients with ischemic heart disease, confirmed by clinical trials, the most attractive clinical applications of I NaL inhibition, heart failure and hypertrophy, remain largely unexplored and deserve further pre-clinical and clinical investigation.
CONCLUSIONS
